Family Medicine Doctors in Higginsville, MO Accepting Medicare
3 Family Medicine doctors found. Showing 1 - 3
 Dr. Matthew David Rhadans, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3401 Pine St, Higginsville, MO 64037 Phone: 660-584-2192 Fax: 660-584-3771 |
Dr. David V Pulliam, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 W 22nd St, Higginsville, MO 64037 Phone: 660-747-7751 |
 Dr. Nadia Parsan, MD Family Medicine - Adolescent Medicine Medicare: Not Enrolled in Medicare Practice Location: 3401 Pine St, Higginsville, MO 64037 Phone: 660-584-2192 |
News Archive
Newly identified gene biomarker can distinguish atopic dermatitis and psoriasis with excellent accuracy
Mount Sinai researchers have pinpointed a single gene biomarker, nitride oxide synthase 2 (NOS2) that can distinguish atopic dermatitis (AD) and psoriasis with 100 percent accuracy using adhesive tape strips, a non-invasive alternative to skin biopsy. The research will be published online today in the Journal of Allergy and Clinical Immunology.
Flightless mosquitoes could fight dengue, study says
By rendering female Aedes aegypti mosquitoes - the dengue virus vector - unable to fly, scientists say they may be able to slow the spread of the virus which experts believe "affects up to 100 million people a year and threatens over a third of the world's population," the BBC reports. Currently, there is no treatment for dengue nor a vaccine to protect against the virus.
AAP recommends limiting screen time to 2 hours per day for preschool-age children
The American Academy of Pediatrics (AAP) recommends that parents limit combined screen time from television, DVDs, computers, and video games to 2 hours per day for preschool-age children. In a study soon to be published in The Journal of Pediatrics, researchers found that many children are exposed to screen time both at home and while at child care, with 66% exceeding the recommended daily amount.
Elevation presents positive data from EP-101 Phase 2a study on COPD at ERS annual meeting
Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today that it presented positive results from a Phase 2a study of EP-101 in patients with moderate to severe chronic obstructive pulmonary disease (COPD), a large and growing disease characterized by significant unmet clinical needs, at the annual meeting of the European Respiratory Society.
BMBF to provide EUR 1.3M to develop MRI using polarized substances
Over the past 30 years, magnetic resonance imaging has evolved into one of the most important imaging procedures in medical diagnostics. With a new approach based on the use of polarized gases and dissolved substances, it will in future be possible to produce even better quality images of the inside of the human body.
› Verified 4 days ago